Ascelia Pharma Unveils Leadership Changes to Foster Future Expansion

Executive Leadership Changes: Ascelia Pharma has announced the recruitment of Anton Hansson as Chief Financial Officer (CFO) and the promotion of Jennie Wilborgsson to Chief Operating Officer (COO) to enhance its operational capabilities.

Management Structure: The executive leadership team now consists of five members, including the CEO, Deputy CEO and CCO, CSO, COO, and CFO, aiming for a streamlined management structure aligned with the company's strategic priorities.

Focus on Growth: CEO Magnus Corfitzen emphasized that these leadership changes are crucial for preparing Ascelia Pharma for its next growth phase, particularly in relation to their drug candidate Orviglance.

Company Overview: Ascelia Pharma, based in Malmö, Sweden, specializes in developing orphan oncology treatments and has two drug candidates, Orviglance and Oncoral, in development.